163 related articles for article (PubMed ID: 35194118)
21.
Shen H; Lundy J; Strickland AH; Harris M; Swan M; Desmond C; Jenkins BJ; Croagh D
Cells; 2022 Oct; 11(19):. PubMed ID: 36231137
[No Abstract] [Full Text] [Related]
22. KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study.
Nakano Y; Kitago M; Matsuda S; Nakamura Y; Fujita Y; Imai S; Shinoda M; Yagi H; Abe Y; Hibi T; Fujii-Nishimura Y; Takeuchi A; Endo Y; Itano O; Kitagawa Y
Br J Cancer; 2018 Mar; 118(5):662-669. PubMed ID: 29360815
[TBL] [Abstract][Full Text] [Related]
23. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
[TBL] [Abstract][Full Text] [Related]
24. Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer.
Hussung S; Akhoundova D; Hipp J; Follo M; Klar RFU; Philipp U; Scherer F; von Bubnoff N; Duyster J; Boerries M; Wittel U; Fritsch RM
BMC Cancer; 2021 Jan; 21(1):49. PubMed ID: 33430810
[TBL] [Abstract][Full Text] [Related]
25. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
[TBL] [Abstract][Full Text] [Related]
26. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
[TBL] [Abstract][Full Text] [Related]
27. Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer.
Hashimoto D; Arima K; Nakagawa S; Negoro Y; Hirata T; Hirota M; Inomata M; Fukuzawa K; Ohga T; Saeki H; Oki E; Yamashita YI; Chikamoto A; Baba H; Maehara Y
J Gastroenterol; 2019 May; 54(5):437-448. PubMed ID: 30515563
[TBL] [Abstract][Full Text] [Related]
28. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.
Schultz NA; Roslind A; Christensen IJ; Horn T; Høgdall E; Pedersen LN; Kruhøffer M; Burcharth F; Wøjdemann M; Johansen JS
Pancreas; 2012 Jul; 41(5):759-66. PubMed ID: 22699145
[TBL] [Abstract][Full Text] [Related]
29. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
30. Perioperative cell-free mutant KRAS dynamics in patients with pancreatic cancer.
Hipp J; Hussung S; Timme-Bronsert S; Boerries M; Biesel E; Fichtner-Feigl S; Fritsch R; Wittel UA
Br J Surg; 2021 Apr; 108(3):239-243. PubMed ID: 33793718
[No Abstract] [Full Text] [Related]
31. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
32. Clinical impact of additional therapy for residual pancreatic cancer.
Yamada S; Sonohara F; Tashiro M; Murotani K; Takami H; Hayashi M; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujii T; Kodera Y
Surg Today; 2020 May; 50(5):440-448. PubMed ID: 31650262
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.
Hadano N; Murakami Y; Uemura K; Hashimoto Y; Kondo N; Nakagawa N; Sueda T; Hiyama E
Br J Cancer; 2016 Jun; 115(1):59-65. PubMed ID: 27280632
[TBL] [Abstract][Full Text] [Related]
34. Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma.
Hashimoto D; Arima K; Yokoyama N; Chikamoto A; Taki K; Inoue R; Kaida T; Higashi T; Nitta H; Ohmuraya M; Hirota M; Beppu T; Baba H
Pancreas; 2016 Sep; 45(8):1111-4. PubMed ID: 26967456
[TBL] [Abstract][Full Text] [Related]
35. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
[TBL] [Abstract][Full Text] [Related]
36. KRAS mutation analysis of washing fluid from endoscopic ultrasound-guided fine needle aspiration improves cytologic diagnosis of pancreatic ductal adenocarcinoma.
Park JK; Lee YJ; Lee JK; Lee KT; Choi YL; Lee KH
Oncotarget; 2017 Jan; 8(2):3519-3527. PubMed ID: 27974679
[TBL] [Abstract][Full Text] [Related]
37. Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated With Smaller Lesions.
Nagawkar SS; Abu-Funni S; Simon E; Bick T; Prinz E; Sabo E; Ben-Izhak O; Hershkovitz D
Pancreas; 2016 Jul; 45(6):876-81. PubMed ID: 26646269
[TBL] [Abstract][Full Text] [Related]
38. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
39. KRAS mutation testing on all non-malignant diagnosis of pancreatic endoscopic ultrasound-guided fine-needle aspiration biopsies improves diagnostic accuracy.
Trisolini E; Armellini E; Paganotti A; Veggiani C; Bozzola C; Frattini M; Pizio C; Mancuso G; Andorno S; Boldorini R
Pathology; 2017 Jun; 49(4):379-386. PubMed ID: 28450086
[TBL] [Abstract][Full Text] [Related]
40. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.
Viale A; Pettazzoni P; Lyssiotis CA; Ying H; Sánchez N; Marchesini M; Carugo A; Green T; Seth S; Giuliani V; Kost-Alimova M; Muller F; Colla S; Nezi L; Genovese G; Deem AK; Kapoor A; Yao W; Brunetto E; Kang Y; Yuan M; Asara JM; Wang YA; Heffernan TP; Kimmelman AC; Wang H; Fleming JB; Cantley LC; DePinho RA; Draetta GF
Nature; 2014 Oct; 514(7524):628-32. PubMed ID: 25119024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
